Skip to main content
SpringerLink
Log in

Development of a lyophilized dosage form of cifelin

  • Published:
Pharmaceutical Chemistry Journal Aims and scope

Freshly prepared liposome dispersions have a limited shelf-life, which hinders large-scale production with subsequent storage and sales to patients. This article addresses the development of a cifelin freeze-dried pegylated liposomal form. The effects of various cryoprotectors (glucose, sucrose, lactose, and mannitol) on the hydrophobic drug entrapment efficiency and its size change in the liposome membrane during storage were studied. The best results were obtained using sucrose with an optimum lipid:cryoprotector ratio of 1:1.4. Quality parameters such as vesicle size, pH value, and cifelin entrapment efficiency for the resulting freeze-dried liposomal dosage form remained unchanged during the studied storage time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. N. A. Chikineva, Z. S. Smirnova, O. L. Orlova, et al., Khim.-farm. Zh., 35(8), 34 – 35 (2001).

    Google Scholar 

  2. N. A. Chikineva, Author’s Abstract of a Candidate Dissertation in Medical Sciences, Moscow (2002).

  3. A. P. Kaplun, L. Shon, Yu. M. Krasnopol’skii, and V. I. Shvets, Vopr. Med. Khim., 45(1),3–12 (1999).

    PubMed  CAS  Google Scholar 

  4. G. Gregoriadis (ed.), Liposome Technology, Vol. 3, Informa Healthcare USA, New York (2007), pp. 79 – 94.

  5. Yu. M. Krasnopol’skii, A. E. Stepanov, and V. I. Shvets, Khim.-farm. Zh., 33(10), 20 – 23 (1999).

    Google Scholar 

  6. G. Gregoriadis (ed.), Liposome Technology, Vol. 1, Informa Healthcare USA, New York (2007), pp. 261 – 281.

  7. A. S. Dudnichenko, Provizor, No. 19, 24 – 25 (2000).

  8. N. Odintsova, K. Kiselev, N. Sanina, et al., CryoLetters, 22, 299 – 310 (2001).

    PubMed  CAS  Google Scholar 

  9. M. M. Nounou, L. El-Khordagui, N. Khallafallah, et al., DARU, 13(4), 133 – 142 (2005).

    CAS  Google Scholar 

  10. M. C. Woodle and D. D. Losic, Biochim. Biophys. Acta, 1113, 171 – 199 (1992).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blokhin State Cancer Research Center, Russian Academy of Medical Sciences, Moscow, 115478, Russia

    E. A. Kotova, E. V. Ignat’eva, O. L. Orlova & N. A. Oborotova

  2. Sechenov First Moscow State Medical University, Moscow, 119991, Russia

    I. I. Krasnyuk

Authors
  1. E. A. Kotova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. V. Ignat’eva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. L. Orlova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. I. Krasnyuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. A. Oborotova
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 46, No. 5, pp. 39 – 42, May, 2012.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kotova, E.A., Ignat’eva, E.V., Orlova, O.L. et al. Development of a lyophilized dosage form of cifelin. Pharm Chem J 46, 299–302 (2012). https://doi.org/10.1007/s11094-012-0784-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-012-0784-2

Key words

Search

Navigation